Prof William Rosenberg

Photo

Personal Profile

Name: William Rosenberg Email: w.rosenberg@ucl.ac.uk
Title: Prof Tel: 0207 794 0500
Department: lnstitute of Liver and Digestive Health Fax:
Position: Peter Scheuer Chair of Liver Disease Address: Royal Free Hospital, Pond Street, London, NW3 2QG
Research Domain: Experimental Medicine, Infection, Immunology & Inflammation, Neuroscience, Personalised Medicine, Populations & Lifelong Health Web Page:  

Profile

Research Description

The Group has a long-standing interest in the immune response to hepatitis viruses. We have built upon knowledge of the interactions between host and viruses to develop vaccines for the prophylaxis and treatment of viral hepatitis. In addition we investigate biomarkers of liver fibrosis. Our work has led to the identification of a panel of markers that can determine the severity of liver fibrosis and prognosis. We are currently undertaking further research to identify new markers of liver fibrosis using metabonomics and proteomics. The Group also initiates and participates in clinical studies ranging from epidemiology to clinical trials of drugs and diagnostic tests.

Research Activities

Clinical trials

Hepatology

Immunopathogenesis of hepatitis B virus infection

Education Description

I was a founder member of the Center for Evidence Based Medicine in Oxford and an author of the textbook Evidence Based Medicine. I have lectured and taught extensively throughout Europe and North America on the subject.

UCL Collaborators

Prof Janet Darbyshire; Prof Mala Maini; Dr Michael Jacobs; Mr Hashim Ahmed; Prof Geoffrey Dusheiko; Dr Richard Gilson; Prof Arne Akbar; Dr Zarnie Khadjesari; Prof Mary Collins; Prof Dame Anne Johnson; Prof Elizabeth Murray; Prof Paul Wallace; Prof Irwin Nazareth; Dr Ailbhe Mcdonald; Prof Francesco Muntoni

External Collaborators

Publications

    2014

    • Petersen JR, Stevenson HL, Snyder N, Kasturi KS, Naniwadekar A, Parkes J, Cross R, Rosenberg WM, Xiao S-Y (2014). Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C. Journal of Clinical Gastroenterology, 48(4), 370 - 376. doi:10.1097/MCG.0b013e3182a87e78
    • Abignano G, Cuomo G, Buch MH, Rosenberg WM, Valentini G, Emery P, Del Galdo F (2014). The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis.. Ann Rheum Dis, 73(2), 420 - 427. doi:10.1136/annrheumdis-2012-202843
    • Abignano G, Buch MH, Emery P, Del Galdo F, Cuomo G, Valentini G, Rosenberg WM (2014). The enhanced liver fibrosis test: A clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 73(2), 420 - 427. doi:10.1136/annrheumdis-2012-202843
    • Macartney MJ, Irish D, Bridge SH, Garcia-Diaz A, Booth CL, McCormick AL, Labbett W, Smith C, Velazquez C, Tanwar S, Trembling P, Jacobs M, Dusheiko G, Rosenberg W, Haque T (2014). Telaprevir or Boceprevir Based Therapy for Chronic Hepatitis C Infection: Development of Resistance Associated Variants in Treatment Failure.. Antiviral Res, , - . doi:10.1016/j.antiviral.2014.02.019

    2013

    • Ingegnoli F, Gualtierotti R, Schioppo T, Orenti A, Boracchi P, Lubatti C, Murgo A, Zeni S, Mastaglio C, Galbiati V, Monti G, Grossi C, Borghi O, Rosenberg W, Meroni PL (2013). HOW EARLY STARTS INCREASED COLLAGEN SYNTHESIS IN SYSTEMIC SCLEROSIS?. ANNALS OF THE RHEUMATIC DISEASES, 72, 510 - 510.
    • Abignano G, Cuomo G, Buch M, Rosenberg WM, Valentini G, Emery P, Del Galdo F (2013). SUB-ANALYSIS OF ELF SCORE BIOMARKERS COMPONENTS INDICATES A SPECIFIC CORRELATION WITH DIFFERENT ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS. ANNALS OF THE RHEUMATIC DISEASES, 72, 510 - 511.
    • Godbole G, Irish D, Basarab M, Mahungu T, Fox-Lewis A, Thorne C, Jacobs M, Dusheiko G, Rosenberg WM, Suri D, Millar AD, Nastouli E (2013). Management of hepatitis B in pregnant women and infants: a multicentre audit from four London hospitals.. BMC Pregnancy Childbirth, 13(1), 222 - . doi:10.1186/1471-2393-13-222
    • Tanwar S, Parkes J, Trembling PM, Hogan BJ, Schuppan D, Pinzani M, Arthur MJ, Burt A, Rosenberg WM (2013). FURTHER VALIDATION OF TERMINAL PEPTIDE OF PROCOLLAGEN III (PIIINP) FOR THE DETECTION AND ASSESSMENT OF NONALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    • Trembling PM, Apostolidou S, Parkes J, Ryan A, Gentry-Maharaj A, Tanwar S, Menon U, Rosenberg WM (2013). INFLUENCE OF BMI AND ALCOHOL ON LIVER-RELATED MORBIDITY AND MORTALITY IN A COHORT OF 108,000 WOMEN FROM THE GENERAL POPULATION FROM UKCTOCS.
    • Macdonald DC, Singh H, Whelan MA, Escors D, Arce F, Bottoms SE, Barclay WS, Maini M, Collins MK, Rosenberg WC (2013). Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease.. Mucosal Immunol, , - . doi:10.1038/mi.2013.27
    • Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM (2013). Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.. Hepatology, 57(1), 103 - 111. doi:10.1002/hep.26030
    • Rosenberg WM, Tanwar S, Trembling P (2013). Complexities of HCV management in the new era of direct-acting antiviral agents.. QJM, , - . doi:10.1093/qjmed/hct181
    • Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM (2013). Treatment decisions and contemporary versus pending treatments for hepatitis C.. Nat Rev Gastroenterol Hepatol, , - . doi:10.1038/nrgastro.2013.163
    • Velazquez C, Macartney M, Irish D, Tanwar S, Trembling P, Hogan B, Catt J, Glasgow S, Ju M, Moore MT, Hains M, Smith B, Suri D, Jacobs MG, Oben J, Smith P, Booth C, Bridge S, Garcia A, McCormick A, Nastouli E, Dusheiko GM, Rosenberg W, Haque T (2013). TIMING AND CHARACTERISTICS OF DRUG RESISTANCE MUTATIONS (DRMS) IN CHRONIC HEPATITIS C PATIENTS DURING AND AFTER TREATMENT WITH PROTEASE INHIBITOR THERAPY AT A SINGLE CENTRE.
    • Trembling PM, Tanwar S, Rosenberg WM, Lampertico P, Viganò M, Facchetti F, Colombo M, Parkes J (2013). Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. Journal of Viral Hepatitis, , - . doi:10.1111/jvh.12161
    • Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, Nastouli E, Tanwar S, Rosenberg W, Maini MK (2013). The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells.. PLoS Pathog, 9(3), e1003208 - . doi:10.1371/journal.ppat.1003208
    • Ingegnoli F, Gualtierotti R, Schioppo T, Orenti A, Boracchi P, Lubatti C, Mastaglio C, Galbiati V, Murgo A, Zeni S, Grossi C, Borghi O, Rosenberg W, Castelnovo L, Meroni Pier L (2013). Fibrosis biomarkers in isolated Raynaud's phenomenon: too little, too soon?. Ann Rheum Dis, , - . doi:10.1136/annrheumdis-2013-204009

    2012

    • Velazquez C, Macartney MJ, Irish DN, Tanwar S, Trembling PM, Hogan BJ, Catt J, Glasgow S, Winter L, Ju M, Moore MT, Hains M, Smith B, Suri D, Jacobs M, Oben JA, Nastouli E, Booth CL, Bridge S, Garcia-Diaz A, McCormick AL, Dusheiko G, Rosenberg WM, Haque T (2012). The impact of virologic resistance and adherence on treatment failure in a cohort of hepatitis C virus (HCV) infected patients treated with telaprevir (TVR) and boceprevir (BOC).
    • Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM (2012). Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.. Eur J Gastroenterol Hepatol, 24(5), 543 - 550. doi:10.1097/MEG.0b013e3283513e69
    • Tanwar S, Trembling PM, Hogan BJ, Thorburn D, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM (2012). An algorithm combining direct and indirect liver fibrosis tests enhances diagnostic performance for the detection of advanced fibrosis (F3-4) in NAFLD minimising the need for liver biopsy.
    • Parkes J, Guha IN, Harris S, Rosenberg WM, Roderick PJ (2012). Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease.. Comp Hepatol, 11(1), 5 - . doi:10.1186/1476-5926-11-5
    • McLernon DJ, Dillon JF, Sullivan FM, Donnan PT, Roderick P, Rosenberg WM, Ryder SD (2012). The Utility of Liver Function Tests for Mortality Prediction within One Year in Primary Care Using the Algorithm for Liver Function Investigations (ALFI). PLoS ONE, 7(12), - . doi:10.1371/journal.pone.0050965
    • Wahl K, Manns MP, Bantel H, Rosenberg W, Vaske B, Schulze-Osthoff K, Bahr MJ (2012). Biopsy-Controlled Liver Fibrosis Staging Using the Enhanced Liver Fibrosis (ELF) Score Compared to Transient Elastography. PLoS ONE, 7(12), - . doi:10.1371/journal.pone.0051906
    • Rodger AJ, Tedder RS, Fries L, Ijaz S (2012). The diversity and management of chronic hepatitis B virus infections in the UK – A wake up call. Clinical Infectious Diseases, , - .
    • Abignano G, Cuomo G, Buch MH, Rosenberg WM, Valentini G, Emery P, Del Galdo F (2012). Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis.
    • Tanwar S, Trembling PM, Thorburn D, Guha IN, Parkes J, Kaye P, Burt A, Ryder SD, Aithal G, Day C, Rosenberg WM (2012). DIRECT SERUM MARKERS ARE MORE ACCURATE THAN SIMPLE MARKER PANELS FOR THE DETECTION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). GUT, 61, A414 - A414. doi:10.1136/gutjnl-2012-302514d.286
    • Tanwar S, Trembling PM, Ellis E, Parkes J, Herold C, Schuppan D, Rosenberg WMC (2012). DIRECT NON-INVASIVE SERUM MARKERS OF LIVER FIBROSIS PREDICT FIBROSIS EVOLUTION IN CHRONIC HEPATITIS C BUT ARE INCREASED BY INTERFERON-BASED THERAPY. GUT, 61, A143 - A144. doi:10.1136/gutjnl-2012-302514b.172
    • Trembling PM, Parkes J, Tanwar S, Burt AD, Rosenberg WM (2012). ENHANCED LIVER FIBROSIS TEST ACCURATELY IDENTIFIES LIVER FIBROSIS AND PREDICTS CLINICAL OUTCOMES IN ALCOHOLIC LIVER DISEASE. GUT, 61, A408 - A409. doi:10.1136/gutjnl-2012-302514d.273
    • Ingegnoli F, Gualtierotti R, Schioppo T, Orenti A, Boracchi P, Lubatti C, Rizzini SL, Murgo A, Zeni S, Mastaglio C, Galbiati V, Grossi C, Borghi M, Rosenberg WM, Meroni PL (2012). Enhanced Liver Fibrosis Test: A Further Step Toward Depiction of Fibrotic Process in Very Early Diagnosis of Systemic Sclerosis.
    • Khan SA, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WMC, Tait P, Wasan H (2012). Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update. Gut, 61(12), 1657 - 1669. doi:10.1136/gutjnl-2011-301748
    • Trembling PM, Cheung M, Tanwar S, Rosenberg WM (2012). CONCORDANCE OF NON-INVASIVE MARKERS OF LIVER FIBROSIS IN A MIXED POPULATION OF LIVER DISEASES. GUT, 61, A408 - A408. doi:10.1136/gutjnl-2012-302514d.272
    • Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Rosenberg W, Maini MK (2012). The third signal cytokine IL-12 rescues anti-viral responses in exhausted CD8 T cells.
    • Hogan B, Trembling PM, Tanwar S, Yu D, O'Beirne JP, Rosenberg WM (2012). DO ALL REGENERATIVE NODULES BECOME HEPATOCELLULAR CARCINOMA? THE OUTCOME OF 4 YEARS MRI SURVEILLANCE. GUT, 61, A192 - A192. doi:10.1136/gutjnl-2012-302514c.21
    • Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y, Rosenberg W, Dusheiko G, Gilson R, ChinAleong J, Kennedy P, Maini MK (2012). Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection.. PLoS One, 7(10), e47648 - . doi:10.1371/journal.pone.0047648
    • Deuffic-Burban S, Deltenre P, Mathurin P, Buti M, Stroffolini T, Parkes J, Mühlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W, Zeuzem S (2012). Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology, 143(4), - . doi:10.1053/j.gastro.2012.05.054
    • Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H, British Society of Gastroenterology (2012). Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update.. Gut, 61(12), 1657 - 1669. doi:10.1136/gutjnl-2011-301748
    • Trembling PM, Parkes J, Tanwar S, Burt AD, Rosenberg WM, Investigators ELF (2012). ENHANCED LIVER FIBROSIS TEST ACCURATELY IDENTIFIES LIVER FIBROSIS AND PREDICTS CLINICAL OUTCOMES IN ALCOHOLIC LIVER DISEASE.
    • Hogan BJ, Trembling PM, Tanwar S, Yu D, O'Beirne JP, Rosenberg WM (2012). DO ALL ARTERIALISED NODULES BECOME HEPATOCELLULAR CARCINOMA? THE OUTCOME OF 4 YEARS MAGNETIC RESONANCE IMAGING SURVEILLANCE.
    • Tanwar S, Trembling PM, Thorburn D, Guha IN, Parkes J, Kaye P, Burt A, Ryder SD, Aithal G, Day C, Rosenberg WM (2012). DIRECT SERUM MARKERS ARE MORE ACCURATE THAN SIMPLE MARKER PANELS FOR THE DETECTION OF FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD).
    • Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (2012). [What is EBM and what is not?].. Neuere Med Wiss Quellen Stud, 22, 13 - 17.
    • Abignano G, Cuomo G, Buch M, Rosenberg WM, Valentini G, Emery P, Del Galdo F (2012). ELF SCORE: A VALIDATED SERUM TEST STRONGLY PREDICTIVE OF FIBROSIS IN SSc.
    • Abignano G, Cuomo G, Buch MH, Rosenberg WM, Valentini G, Emery P, Del Galdo F (2012). ELF SCORE: A VALIDATED SERUM TEST STRONGLY PREDICTIVE OF FIBROSIS IN SYSTEMIC SCLEROSIS.
    • Tanwar S, Trembling PM, Ellis E, Parkes J, Herold C, Schuppan D, Rosenberg WM (2012). DIRECT NON-INVASIVE SERUM MARKERS OF LIVER FIBROSIS PREDICT FIBROSIS EVOLUTION IN CHRONIC HEPATITIS C BUT ARE INCREASED BY INTERFERON-BASED THERAPY.
    • Tanwar S, Rosenberg WM, Foster GR, Wright M, Parkes J, Ryder SD, Mills PR, Cramp ME (2012). Randomized clinical trial: A pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis. European Journal of Gastroenterology and Hepatology, 24(5), 543 - 550. doi:10.1097/MEG.0b013e3283513e69
    • Ruth ND, Rosenberg WM, Sharif K, McKiernan PJ (2012). The predictive value of ELF test in patients with biliary atresia.

    2011

    • Schurich A, Pallett L, Lubowiecki M, Singh H, Rosenberg W, Maini M (2011). Interleukin 12 mediated recovery of effector cytokine production in hepatitis B virus-specific CD8+T cells.
    • Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, Irving W, Zaitoun A, Wheatley M, Ryder S, Rosenberg W (2011). Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C.. J Viral Hepat, 18(1), 23 - 31. doi:10.1111/j.1365-2893.2009.01263.x
    • Peppa D, Gill U, Micco L, Schurich A, Nebbia G, Singh H, Rosenberg W, Gilson R, Kennedy PT, Maini M (2011). Susceptibility of T cells to death ligand-mediated deletion in the liver of chronic hepatitis B virus (CHB) infected patients.
    • Darbyshire J, Sitzia J, Cameron D, Ford G, Littlewood S, Kaplan R, Johnston D, Matthews D, Holloway J, Chaturvedi N, Morgan C, Riley A, Rossor M, Kotting P, McKeith I, Smye S, Gower J, Brown V, Smyth R, Poustie V, van't Hoff W, Wallace P, Ellis T, Wykes T, Burns S, Rosenberg W, Lester N, Stead M, Potts V, Johns C, Campbell H, Hamilton R, Sheffield J, Selby P (2011). Extending the clinical research network approach to all of healthcare.. In (Ed.), (pp. vii36 - vii43). : . doi:10.1093/annonc/mdr424
    • Trembling PM, Lampertico P, Parkes J, Tanwar S, Vigano M, Facchetti F, Colombo M, Rosenberg WM (2011). COMPARISON OF ENHANCED LIVER FIBROSIS TEST AND TRANSIENT ELASTOGRAPHY FOR THE NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS B.
    • Abignano G, Cuomo G, Buch MH, Rosenberg WM, Valentini G, Emery P, Del Galdo F (2011). ELF Score: A Validated Serum Test Strongly Predictive of Fibrosis in Systemic Sclerosis..
    • Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM (2011). VALIDATION OF A NOVEL BIOMARKER MODEL FOR THE PREDICTION OF NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE.
    • Schurich A, Khanna P, Lubowiecki M, Lopes AR, Peppa D, Micco L, Nebbia G, Singh H, Rosenberg W, Kennedy PTF, Dusheiko G, Maini M (2011). ALTERING CO-INHIBITORY AND CO-STIMULATORY PATHWAYS TO RESTORE ANTI-VIRAL T CELL RESPONSES IN CHRONIC HBV INFECTION.
    • Peppa D, Micco L, Schurich A, Nebbia G, Khanna P, Singh H, Rosenberg W, Dusheiko G, Gilson R, Maini M (2011). FRATRICIDE OF HBV-SPECIFIC CD8 T CELLS BY NK CELLS MEDIATED THROUGH THE TRAIL PATHWAY.
    • Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Muehlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W, Zeuzem S, Mathurin P (2011). HCV BURDEN IN EUROPE: IMPACT OF NATIONAL TREATMENT PRACTICES ON FUTURE HCV-RELATED MORBIDITY AND MORTALITY THROUGH A MODELING APPROACH.
    • Stroffolini T, Deuffic-Burban S, Deltenre P, Buti M, Parkes J, Muehlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W, Zeuzem S, Mathurin P (2011). HCV burden in Europe: Impact of national treatment practices on future HCV-related morbidity and mortality through a modeling approach. DIGESTIVE AND LIVER DISEASE, 43, S70 - S70.
    • Barker J, Horn EJ, Lebwohl M, Warren RB, Nast A, Rosenberg W, Smith C, International Psoriasis Council (2011). Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic.. J Eur Acad Dermatol Venereol, 25(7), 758 - 764. doi:10.1111/j.1468-3083.2010.03932.x
    • Trépo E, Potthoff A, Pradat P, Bakshi R, Young B, Lagier R, Moreno C, Verset L, Cross R, Degré D, Lemmers A, Gustot T, Berthillon P, Rosenberg W, Trépo C, Sninsky J, Adler M, Wedemeyer H (2011). Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease.. J Hepatol, 55(1), 38 - 44. doi:10.1016/j.jhep.2010.10.018
    • Tanwar S, Ellis EL, Parkes J, Herold C, Rosenberg WM (2011). Changes in ELF Score During Treatment With Pegylated Interferon and Silymarin Are Associated With Progression of Histological Liver Disease in Non-Responder Patients With Chronic Hepatitis C.
    • Fowell AJ, Collins JE, Duncombe DR, Pickering JA, Rosenberg WMC, Benyon RC (2011). Silencing tissue inhibitors of metalloproteinases (TIMPs) with short interfering RNA reveals a role for TIMP-1 in hepatic stellate cell proliferation. BIOCHEM BIOPH RES CO, 407(2), 277 - 282. doi:10.1016/j.bbrc.2011.02.009
    • Tanwar S, Ellis E, Parkes J, Herold C, Rosenberg W (2011). CHANGES IN ELF SCORE DURING TREATMENT WITH PEGYLATED INTERFERON AND SILYMARIN ARE ASSOCIATED WITH PROGRESSION OF HISTOLOGICAL LIVER DISEASE IN NON-RESPONDER PATIENTS WITH CHRONIC HEPATITIS C. doi:10.1136/gut.2011.239301.527
    • Tanwar S, Ellis E, Parkes J, Herold C, Rosenberg W (2011). CHANGES IN ELF SCORE DURING TREATMENT WITH PEGYLATED INTERFERON AND SILYMARIN ARE ASSOCIATED WITH PROGRESSION OF HISTOLOGICAL LIVER DISEASE IN NON-RESPONDER PATIENTS WITH HEPATITIS C.
    • Alkhouri N, Carter-Kent C, Lopez R, Rosenberg WM, Pinzani M, Bedogni G, Feldstein AE, Nobili V (2011). A Combination of the Pediatric NAFLD Fibrosis Index and Enhanced Liver Fibrosis Test Identifies Children With Fibrosis. CLIN GASTROENTEROL H, 9(2), 150 - 155. doi:10.1016/j.cgh.2010.09.015
    • Nebbia G, Peppa D, Schurich A, Khanna P, Singh H, Rosenberg W, Dusheiko G, Gilson R, Chinaleong J, Kennedy P, Maini M (2011). Role of the TIM-3/Galectin-9 pathway in chronic hepatitis B infection.

    2010

    • Evans A, Rosenberg W (2010). Management of HCV in Patients with Psychiatric Comorbidity. Clinical Dilemmas in Viral Liver Disease, , 58 - 60. doi:10.1002/9781444319590.ch13
    • Whelan M, El-Turabi A, Beales L, Maucourant S, Rosenberg WM (2010). A DUAL INSERT HEPATITIS B TANDEM CORE VACCINE ELICITS STRONG HBV IMMUNE RESPONSES AND SIMULTANEOUSLY CONFERS PROTECTIVE IMMUNITY IN AN INFLUENZA MODEL.
    • Fries L, Rodger A, Ijaz S, Moreea S, Bathgate A, Wong T, Rosenberg WM, Bassendine MF, Mills PR, Ryder SD, Mutimer DJ, Dusheiko GM, Jacobs M, Dillon JF, Anderson M, Collier JD, Hussaini H, Bird G, Tedder RS, Rosenberg G, Banatvala J, Williams R, Naoumov NV, Chokshi S, Thursz MR, Johnson A (2010). CHRONIC HEPATITIS B VIRUS INFECTION IN THE UK: A MULTICENTRE STUDY OF CLINICAL AND VIROLOGICAL CHARACTERISTICS.
    • Fowell AJ, Sanchez-Elsner T, Benyon RC, Rosenberg WM, Collins JE (2010). DIFFERENTIAL EXPRESSION OF MICRORNAS DURING HEPATIC STELLATE CELL (HSC) ACTIVATION AND THEIR ROLE IN THE REGULATION OF HSC PROLIFERATION AND APOPTOSIS.
    • Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Muehlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg WM, Zeuzem S, Mathurin P (2010). HCV BURDEN IN EUROPE: IMPACT OF NATIONAL TREATMENT PRACTICES ON FUTURE HCV-RELATED MORBIDITY AND MORTALITY THROUGH A MODELING APPROACH.
    • Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM (2010). INDIVIDUALIZED CONCENTRATION MONITORED HIGH DOSE RIBAVIRIN IN COMBINATION WITH PEGINTERFERON TO HEPATITIS C GENOTYPE 1 PATIENTS WITH PREVIOUS NONRESPONSE.
    • Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J, Lombard M, Alexander G, Ramage J, Dusheiko G, Wheatley M, Gough C, Burt A, Rosenberg W (2010). Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. GUT, 59(9), 1245 - 1251. doi:10.1136/gut.2009.203166
    • Tanwar S, Ellis EL, Herold C, Rosenberg WM (2010). NON-INVASIVE ASSESSMENT OF HEPATIC FIBROSIS IN PRIOR NON-RESPONDERS TO HCV TREATMENT- A COMPARISON OF 8 MARKER PANELS OF LIVER FIBROSIS.
    • Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM (2010). PACIFIC: A PHASE III, RANDOMIZED, MULTICENTER, DOSE ESCALATION, EFFICACY AND SAFETY STUDY EXAMINING THE EFFECTS OF TREATMENT WITH PEGINTERFERON ALFA-2A IN PATIENTS WITH CHILD'S A OR B CIRRHOSIS IN CHRONIC HEPATITIS C VIRUS INFECTION.
    • Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, Little AM, Alexander GJ, Rosenberg WMC, Cramp ME, Khakoo SI (2010). Consistent Beneficial Effects of Killer Cell Immunoglobulin-Like Receptor 2DL3 and Group 1 Human Leukocyte Antigen-C Following Exposure to Hepatitis C Virus. HEPATOLOGY, 51(4), 1168 - 1175. doi:10.1002/hep.23477
    • Macdonald DC, Whelan M, Escors D, Rosenberg WMC, Collins MK (2010). Lentiviral Vectors Encoding Influenza A Nucleprotein and vFLIP Induce Potent CD8 T-Cell Responses and Confer Protection Against Lethal Flu Challenge.
    • Fries L, Rodger A, Dusheiko G, Ijaz S, Tedder R, Banatvala J, Williams R, Naoumov N, Puranik S, Chokshi S, Wong T, Rosenberg W, Moreea S, Bathgate A, Jacobs M, Mills P, Mutimer D, Bassendine M, Ryder S, Thursz M, Johnson A (2010). COLLABORATIVE UK STUDY OF CHRONIC HEPATITIS B VIRUS INFECTION.
    • Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C (2010). Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.. BMC Gastroenterol, 10, 103 - . doi:10.1186/1471-230X-10-103
    • Macdonald D, Brindle NR, Whelan M, Maini MK, Collins MK, Rosenberg WM (2010). LENTIVIRAL VECTORS CO-EXPRESSING HEPATITIS-B CORE AND VFLIP INDUCE POTENT CD8 T-CELL AND ANTIBODY RESPONSES IN HLA-A2 TRANSGENIC MICE.

    2009

    • Donnan PT, McLernon D, Dillon JF, Ryder S, Roderick P, Sullivan F, Rosenberg W (2009). Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE).. Health technology assessment (Winchester, England), 13(25), - .
    • McLernon DJ, Donnan PT, Ryder S, Roderick P, Sullivan FM, Rosenberg W, Dillon JF (2009). Health outcomes following liver function testing in primary care: a retrospective cohort study.. Fam Pract, 26(4), 251 - 259. doi:10.1093/fampra/cmp025
    • Dillon PW, Parkes J, Harris S, Cross R, Burt A, Rosenberg W (2009). The Clinical Performance of the Immunol (TM) Enhanced Liver Fibrosis (ELF (TM)) Score Is Robust to the Biopsy Staging System and Dichotomization Level Used to Fit Its Coefficients. CLINICAL CHEMISTRY, 55(6), A169 - A169.
    • Libri NA, Barker SJ, Rosenberg WMC, Semper AE (2009). A class C CpG toll-like receptor 9 agonist successfully induces robust interferon-alpha production by plasmacytoid dendritic cells from patients chronically infected with hepatitis C. J VIRAL HEPATITIS, 16(5), 315 - 324. doi:10.1111/j.1365-2893.2008.01011.x
    • Donnan PT, McLernon D, Dillon JF, Ryder S, Roderick P, Sullivan F, Rosenberg W (2009). Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE).. Health Technol Assess, 13(25), iii - 134. doi:10.3310/hta13250
    • Bryant J, Cooper K, Picot J, Clegg A, Roderick P, Rosenberg W, Patch C (2009). Diagnostic strategies using DNA testing for hereditary haemochromatosis in at-risk populations: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 13(23), 1 - +.
    • Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, Vizzutti F, Pinzani M, Rosenberg WM (2009). Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease.. Gastroenterology, 136(1), 160 - 167. doi:10.1053/j.gastro.2008.09.013
    • Bryant J, Cooper K, Picot J, Clegg A, Roderick P, Rosenberg W, Patch C (2009). Diagnostic strategies using DNA testing for hereditary haemochromatosis in at-risk populations: a systematic review and economic evaluation.. Health Technol Assess, 13(23), iii - 126. doi:10.3310/hta13230
    • He Y, Barker SJ, MacDonald AJ, Yu Y, Cao L, Li J, Parhar R, Heck S, Hartmann S, Golenbock DT, Jiang S, Loibri NA, Semper AE, Rosenberg WM, Lustigman S (2009). Recombinant Ov-ASP-1, a Th1-Biased Protein Adjuvant Derived from the Helminth Onchocerca volvulus, Can Directly Bind and Activate Antigen-Presenting Cells. JOURNAL OF IMMUNOLOGY, 182(7), 4005 - 4016. doi:10.4049/jimmunol.0800531
    • Picot J, Bryant J, Cooper K, Clegg A, Roderick P, Rosenberg W, Patch C (2009). Psychosocial aspects of DNA testing for hereditary hemochromatosis in at-risk individuals: a systematic review.. Genet Test Mol Biomarkers, 13(1), 7 - 14. doi:10.1089/gtmb.2008.0064
    • Donnan PT, McLernon D, Sullivan F, Dillon JF, Ryder S, Roderick P, Rosenberg W (2009). Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: A record-linkage population cohort study and decision analysis (ALFIE). Health Technology Assessment, 13(25), - . doi:10.3310/hta13250
    • Bryant J, Cooper K, Picot J, Clegg A, Roderick P, Rosenberg W, Patch C (2009). Diagnostic strategies using DNA testing for hereditary haemochromatosis in at-risk populations: A systematic review and economic evaluation. Health Technology Assessment, 13(23), - . doi:10.3310/hta13230
    • Bryant J, Cooper K, Picot J, Clegg A, Roderick P, Rosenberg W, Patch C (2009). Diagnostic strategies using DNA testing for hereditary haemochromatosis in at-risk populations: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 13(23), - .
    • Barker S, Perkins H, Bannister R, Gore K, Laxton C, Hamilton D, Corey T, Fidock M, Westby M, Parkinson T, Semper A, Rosenberg W (2009). EVALUATION OF THE IMMUNOSTIMULATORY ACTIONS OF THE TLR7 AGONIST SM-360320 IN EX VIVO ASSAYS IN THE BLOOD OF HCV PATIENTS AND HEALTHY DONORS. JOURNAL OF HEPATOLOGY, 50, S316 - S316.

    2008

    • Fowell AJ, Murphy LB, Johal S, Brooks CL, Semper AE, Rosenberg WM (2008). PROMOTION OF HEPATIC STELLATE CELL FIBROGENESIS AND ICAM-1 EXPRESSION BY ANTIGEN SPECIFIC IMMUNE RESPONSES TO HCV.
    • Guha IN, Rosenberg WM (2008). Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities.. Clin Liver Dis, 12(4), 883 - x. doi:10.1016/j.cld.2008.07.010
    • Fowell AJ, Sheron N, Rosenberg WMC (2008). Renal hepatitis C in the absence of detectable serum or hepatic virus. LIVER INT, 28(6), 889 - 891. doi:10.1111/j.1478-3231.2008.01672.x
    • Parkes J, Roderick R, Harris S, Gough C, Wheatley M, Alexander G, Collier J, Day C, Lombard M, Mutimer D, Ramage J, Dusheiko G, Burt A, Sampson EL, Rosenberg W (2008). Enhanced liver fibrosis (ELF) score predicts clinical outcome in patients with chronic liver disease.
    • Petersen JR, Snyder N, Kasturi K, Naniwadeka A, Sampson E, Parkes J, Cross R, Rosenberg W (2008). Evaluation of the APRI (AST, platelet ratio index) and ELF (TM) (enhanced liver fibrosis) Tests to detect significant fibrosis due to chronic hepatitis C.
    • Fowell AJ, Murphy LB, Johal S, Brooks CL, Semper AE, Brooks CR, Rosenberg WMC (2008). Antigen specific immune responses to HCV promote hepatic stellate cell fibrogenesis and ICAM-1 expression.
    • Parkes J, Smith M, Young A, Rosenberg WM, Roderick PJ (2008). Missed opportunities for referral in chronic liver disease (CLD).
    • Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM (2008). Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.. Hepatology, 47(2), 455 - 460. doi:10.1002/hep.21984
    • Parkes J, Roderick P, Harris S, Gough C, Wheatley M, Alexander G, Collier J, Day C, Lombard M, Mutimer D, Ramage J, Dusheiko G, Burt A, Sampson E, Rosenberg W (2008). European liver fibrosis markers can predict clinical outcome in patients with chronic liver disease.
    • Fowell AJ, Rosenberg WMC, Benyon RC (2008). Silencing timps with sirna: defining a role for TIMP-1 in hepatic stellate cell proliferation.
    • Parkes J, Guha I, Harris S, Rosenberg WMC, Roderick PJ (2008). Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease.
    • Barker SJ, Semper AE, Rosenberg WM (2008). The effect of ribavirin on dendritic cell maturation and cytokine production. doi:10.1016/S0168-8278(08)60013-6
    • Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB, Saldana S, Getachew Y, Butsch R, Luketic V, Peters M, Di Bisceglie A, Bass N, Lake J, Boyer T, Martinez E, Boyer J, Garcia-Tsao G, Barnes D, Rosenberg WM (2008). Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.. Hepatology, 48(5), 1549 - 1557. doi:10.1002/hep.22517
    • Parkes J, Roderick P, Harris S, Gough C, Wheatley M, Alexander G, Collier J, Day C, Lombard M, Mutimer D, Ramage J, Burt A, Dusheiko G, Sampson E, Cross R, Aithal G, Mayo M, Peters M, Irving W, Ryder S, Manos M, Rosenberg W (2008). European liver fibrosis panel of serum markers can predict serious fibrosis on biopsy and clinical outcome in patients with mixed aetiology chronic liver disease. J EPIDEMIOL COMMUN H, 62, A35 - A36.
    • Parkes J, Smith M, Young A, Rosenberg W, Roderick P (2008). Missed opportunities for referral in chronic liver disease. J EPIDEMIOL COMMUN H, 62, A27 - A27.
    • Cooper K, Bryant J, Picot J, Clegg A, Roderick PR, Rosenberg WM, Patch C (2008). A decision analysis model for diagnostic strategies using DNA testing for hereditary haemochromatosis in at risk populations.. QJM, 101(8), 631 - 641. doi:10.1093/qjmed/hcn070
    • MacDonald AJ, Libri NA, Lustigman S, Barker SJ, Whelan MA, Semper AE, Rosenberg WM (2008). A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action.. Clin Exp Immunol, 152(2), 265 - 273. doi:10.1111/j.1365-2249.2008.03623.x
    • Phillips S, Ijaz S, Newman AU, Eren R, Dagan S, Rosenberg W, Chokshi S, Naoumov NV (2008). Novel mechanism of action of anti-HBS antibodies in supressing HBsAG and virus release from hepatoma cells.
    • Fowell AJ, Rosenberg WMC, Benyon RC (2008). Silencing timps with small inhibitory RNA: Defining a role for TIMP-1 in hepatic stellate cell proliferation.
    • Barker SJ, Semper AE, Rosenberg WM (2008). The effects of ribavirin of dendritic cell maturation and cytokine production.
    • Bryant J, Cooper K, Picot J, Clegg A, Roderick P, Rosenberg W, Patch C (2008). A systematic review of the clinical validity and clinical utility of DNA testing for hereditary haemochromatosis type 1 in at-risk populations.. J Med Genet, 45(8), 513 - 518. doi:10.1136/jmg.2007.055806

    2007

    • Parkes J, Roderick P, Harris S, Gough C, Wheatley M, Alexander GJ, Collier JD, Day CP, Mutimer DJ, Ramage J, Burt A, Rosenberg WM (2007). European liver fibrosis (ELF) panel of serum markers can predict clinical outcome in a cohort of patients from England with mixed aetiology chronic liver disease.
    • Rosenberg W, Parkes J, Cross R, Roderick P, Dillon P, Vajdi M, Sampson EL (2007). Analytical and clinical evaluation of the enhanced liver fibrosis (ELF 2) panel.
    • MacDonald AJ, Semper AE, Libri NA, Rosenberg WMC (2007). Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells. CLIN EXP IMMUNOL, 148(3), 494 - 500. doi:10.1111/j.1365-2249.2007.03367.x
    • Rosenberg W (2007). Haemochromatosis. Medicine, 35(2), 89 - 92. doi:10.1016/j.mpmed.2006.11.014
    • Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (2007). Evidence based medicine: what it is and what it isn't. 1996.. Clin Orthop Relat Res, 455, 3 - 5.
    • Donnan PT, McLernon D, Steinke D, Ryder S, Roderick P, Sullivan FM, Rosenberg W, Dillon JF (2007). Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE).. BMC Health Serv Res, 7, 54 - . doi:10.1186/1472-6963-7-54
    • Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS (2007). Evidence based medicine: What it is and what it isn't (reprinted from BMJ, vol 312, pg 71-72, 1996). CLIN ORTHOP RELAT R, (455), 3 - 5. doi:10.1097/BLO.06013e31802fba1e

    2006

    • Mayo MJ, Parks J, Huet B, Combes B, Mills SA, Markin R, Rubin R, Wheeler D, Contos M, West B, Saldana S, Getachew Y, Butsch R, Luketic VA, Peters M, DiBisceglie A, Bass N, Lake JR, Kowdley KV, Boyer TD, Martinez E, Munoz SJ, Boyer JL, Garcia-Tsao G, Rosenberg WM (2006). Serum fibrosis markers predict future clinical decompensation in primary biliary cirrhosis better than liver biopsy, bilirubin, or Mayo Risk score.
    • Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, Bassendine M, Main J, Thomas H (2006). Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.. Gut, 55(9), 1332 - 1338. doi:10.1136/gut.2005.064774
    • Sampson EL, Parkes J, Ryder S, Harris S, Petry C, Anderson-Mauser L, Vajdi M, Rosenberg W (2006). Evaluation of serum markers of liver fibrosis in chronic hepatitis C patients.
    • Parkes J, Cross R, Harris S, Ryder S, Irving W, Zaitoun A, Rosenberg WMC, Trent Hepatitis Res Grp (2006). European liver fibrosis markers accurately distinguish fibrosis severity in chronic hepatitis C.
    • Parkes J, Guha IN, Roderick P, Rosenberg W (2006). Performance of serum marker panels for liver fibrosis in chronic hepatitis C.. J Hepatol, 44(3), 462 - 474. doi:10.1016/j.jhep.2005.10.019
    • Parkes J, Cross R, Harris S, Ryder S, Irving W, Zaitoun A, Rosenberg W (2006). European liver fibrosis markers accurately distinguish fibrosis severity in chronic hepatitis C. doi:10.1016/S0168-8278(06)80549-0
    • Guha IN, Rosenberg WM (2006). Future use of the Glasgow alcoholic hepatitis score.. Gut, 55(1), 135 - 136.
    • Guha IN, Parkes J, Roderick PR, Rosenberg WM (2006). Non-invasive tests of liver fibrosis in NAFLD: A systematic review. doi:10.1016/S0168-8278(06)80688-4
    • Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM (2006). Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.. Gut, 55(11), 1650 - 1660. doi:10.1136/gut.2006.091454
    • Zeuzem S, Alberti A, Rosenberg W, Marcellin P, Diago M, Negro F, Prati D, Puoti C, Roberts SK, Shiffman ML (2006). Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.. Aliment Pharmacol Ther, 24(8), 1133 - 1149. doi:10.1111/j.1365-2036.2006.03073.x
    • Parkes J, Bialek SR, Bell BP, Terrault NA, Zaman A, Sofair AN, Manos MM, Guha IN, Cross R, Harris S, Roderick PJ, Rosenberg WM (2006). European liver fibrosis (ELF) markers accurately distinguish fibrosis severity in chronic hepatitis C (CHC); An external validation study in a population-based cohort.
    • Rosenberg WM, Parkes J, Chattopadhyay D, Burt A, Guha IN, Cross R, Harris S, Roderick PJ, Day C (2006). European liver fibrosis (ELF) markers accurately distinguish fibrosis severity in non alcoholic fatty liver disease (NAFLD); An external validation study.
    • Guha IN, Parkes J, Roderick PJ, Rosenberg WM (2006). Non-invasive markers of fibrosis in NAFLD: A systematic review.
    • Parkes J, Roderick P, Bennett-Lloyd B, Rosenberg W (2006). Variation in hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United Kingdom.. BMC Public Health, 6, 3 - . doi:10.1186/1471-2458-6-3

    2005

    • D'Souza R, Main J, Crossey M, Rosenberg W, Murray-Lyon IM, Hayward C, Foster GR (2005). Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy.. Aliment Pharmacol Ther, 21(1), 43 - 47. doi:10.1111/j.1365-2036.2004.02295.x
    • Park G, Katelaris P, Jones DB, Ngu M, Le Couteur D, Rosenberg W, Poynard T, Ratziu V, Benhamou Y, Thabut D, Moussalli J (2005). Caution before embracing serum markers of liver fibrosis in clinical practice [2] (multiple letters). Gastroenterology, 128(4), 1145 - 1148. doi:10.1053/j.gastro.2005.02.044
    • Rosenberg W (2005). Caution before embracing serum markers of liver fibrosis in clinical practice - Reply. GASTROENTEROLOGY, 128(4), 1146 - 1146. doi:10.1053/j.gastro.2005.02.045
    • Rosenberg W (2005). Biomarkers as a first-line estimate of injury in chronic liver diseases: Time for a moratorium on liver biopsy? Reply. GASTROENTEROLOGY, 128(4), 1148 - 1148. doi:10.1053/j.gastro.2005.02.062
    • Patch C, Roderick P, Rosenberg WMC (2005). Factors affecting the uptake of screening: a randomised controlled non-inferiority trial comparing a genotypic and a phenotypic strategy for screening for haemochromatosis.. Journal of Hepatology, 43(1), 149 - 155. doi:10.1016/j.jhep.2005.02.018
    • Patch C, Roderick P, Rosenberg W (2005). Haemochromatosis: the need for an agreed case definition.. J Hepatol, 43(5), 911 - . doi:10.1016/j.jhep.2005.09.001
    • Patch C, Roderick P, Rosenberg W (2005). Comparison of genotypic and phenotypic strategies for population screening in hemochromatosis: assessment of anxiety, depression, and perception of health.. Genet Med, 7(8), 550 - 556.
    • Guha CIN, Parkes J, Roderick P, Rosenberg W (2005). A systematic review of panels of surrogate non-invasive markers of liver fibrosis in hepatitis C.

    2004

    • Patch C, Roderick P, Rosenberg W (2004). A comparison of a genetic strategy and a biochemical strategy for population screening for haemochromatosis.
    • Cross R, Jewell S, Rosenberg W (2004). HepCgen (R) HCV genotyping for treatment (by real time PCR)..
    • Patch C, Davis A, Gardiner S, Siddel H, Cooper C, Rosenberg WM (2004). Impact of HFE mutations on a birth cohort aged 60..
    • Rosenberg WMC, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ, European LFG (2004). Serum markers detect the presence of liver fibrosis: a cohort study.. Gastroenterology, 127(6), 1704 - 1713. doi:10.1053/j.gastro.2004.08.052
    • Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao XJ, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little AM, Alexander GJ, Cramp ME, O'Brien SJ, Rosenberg WMC, Thomas DL, Carrington M (2004). HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science, 305(5685), 872 - 874. doi:10.1126/science.1097670
    • Patch C, Roderick P, Rosenberg WM (2004). Psychological effects of genetic and biochemical population screenign for hemochromatosis..

    2003

    • Rosenberg WMC (2003). Rating fibrosis progression in chronic liver diseases. J HEPATOL, 38(3), 357 - 360. doi:10.1016/S0168-8278(03)00010-2
    • Bhachu RS, Davis A, Paisey J, Gomez M, Yue A, Roberts PR, Morgan JM, Rosenberg WM (2003). Prevalence of haemochromatosis gene mutations in idiopathic atrial arrhythmias. doi:10.1016/S0195-668X(03)94701-4
    • Khakoo SI, Rosenberg WMC (2003). Emergency management of variceal haemorrhage. CPD Journal Acute Medicine, 2(2), 58 - 63.
    • Bowlus CL, Lee BA, Ravine D, Darke C, Butterworth JR, Cooper BT, Rosenberg WMC, Purkiss M, Jobson S, Hathaway M, Briggs D, Howell WM, Wood GM, Adams DH, Iqbal TH (2003). Discussion on the role of hemochromatosis susceptibility gene mutation in protecting against iron deficiency in celiac disease [5] (multiple letters). Gastroenterology, 124(5), 1562 - 1564.
    • Parkes J, Roderick PJ, Rosenberg WMC, Lloyd BB (2003). Needs assessment for hepatitis C in UK provides information for Europe.
    • Semper A, Libri N, Sanders E, Rosenberg W (2003). Differential expression of the hcv receptor, CD81, on plasmacytoid and myeloid peripheral blood dendritic cells.
    • Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM (2003). Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy.. Gut, 52(10), 1500 - 1504.
    • Patch C, Roderick P, Rosenberg W (2003). Genetic screening for Hemochromatosis is no less acceptable than biochemical screening..
    • Valla D-C, De Franchis R, Hadengue A, Lau GKK, Lavanchy D, Lok AS, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rosenberg W, Rodés J (2003). EASL International Consensus Conference on Hepatitis B: 13-14 September, 2002 Geneva, Switzerland - Consensus statement (short version). Journal of Hepatology, 38(4), 533 - 540. doi:10.1016/S0168-8278(03)00083-7
    • de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodés J, Rosenberg W, Valla D, EASL Jury (2003). EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).. J Hepatol, 39 Suppl 1, S3 - 25.
    • Parkes J, Bennett-Lloyd B, Roderick P, Rosenberg W (2003). National needs assessment for hepatitis C.
    • Wong JB, Rosenberg WM, Manns MP, McHutchison JG, Davis GL, Albrecht JK, Group IHIT (2003). Is peginterferon alfa-2b plus ribavirin cost-effective for treating chronic hepatitis C in the United Kingdom?.
    • Wong JB, Rosenberg WM, Manns MP, Davis GL, McHutchison JG, Albrecht JK, Group IHIT (2003). Evaluating rapid virological response reduces ribavirin and peginterferon alfa-2b treatment costs for chronic hepatitis C in the United Kingdom.
    • Khakoo SI, Brooks CR, Howell M, Alexander GJ, Rosenberg WM (2003). Natural killer (NK) cell receptor genotypes in hepatitis C virus infection.
    • Brooks CR, Rosenberg WM, Khakoo SI (2003). Killer cell immunoglobulin-like receptor (KIR) mRNA expression in natural killer (NK) cells.
    • Semper A, Libri N, Sanders E, Rosenberg W (2003). IL-10 production by dendritic cells is enhanced by cross linking the HCV receptor CD81.
    • Butterworth JR, Cooper BT, Rosenberg WMC, Purkiss M, Jobson S, Hathaway M, Briggs D, Howell WM, Wood GM, Adams DH, Iqbal TH (2003). Discussion on the role of hemochromatosis susceptibility gone mutation in protecting against iron deficiency in Celiac disease - Reply. GASTROENTEROLOGY, 124(5), 1564 - 1564. doi:10.1016/S0016-5085(03)00354-8
    • Foster GR, D'Souza RFC, Main J, Crossey M, Rosenberg W, Murray-Lyon IM, Hayward C (2003). Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy - Is it worthwhile?.
    • Macdonald DC, Leir SH, Brooks C, Sanders E, Lackie P, Rosenberg W (2003). CD44 isoform expression on colonic epithelium mediates lamina propria lymphocyte adhesion and is controlled by Th1 and Th2 cytokines.. Eur J Gastroenterol Hepatol, 15(10), 1101 - 1110. doi:10.1097/01.meg.0000085473.12407.00

    2002

    • Butterworth JR, Rosenberg WMC, Jobson S, Briggs D, Howell WM, Iqbal TH, Cooper BT (2002). South Asian coeliacs resident in Britain possess distinct HLA haplotypes compared with White Caucasian patients. GUT, 50, A90 - A90.
    • Butterworth JR, Rosenberg W, Jobson S, Hathaway M, Briggs D, Howell M, Adams D, Cooper B, Iqbal T (2002). The role of hemochromatosis susceptibility (HFE) gene mutations in protecting against iron deficiency in celiac disease. GASTROENTEROLOGY, 122(4), A179 - A179.
    • (2002). Guidelines for the diagnosis and treatment of cholangiocarcinoma - A consensus document. Gut, 51 (Su, 1 - 9.
    • Rosenberg WM, Benuett-Lloyd B, Parkes J, Roderick P (2002). Differences between antiviral therapy trials may be attributed to chance..
    • Semper AE, Libri N, Sanders E, Rosenberg WM (2002). Differential expression of the HCV receptor, CD81, on plasmacytoid and myeloid peripheral blood dendritic cells..
    • Brooks C, Murphy L, Sanders E, Rosenberg W (2002). ICAM-1 expression on human hepatic stellate cells as an indicator of hepatitis C specific immune responses in chronic hepatitis C. GASTROENTEROLOGY, 122(4), A677 - A677.
    • Brooks CL, Sanders EA, Hadfield S, Green S, Rosenberg WM (2002). Changes in HCV specific CD4(+) responses during treatment with pegylated interferon-alpha and ribavirin correlate with viral response. GUT, 50, A48 - A48.
    • Butterworth JR, Rosenberg WMC, Jobson S, Hathaway M, Briggs D, Howell WM, Adams DH, Cooper BT, Iqbal TH (2002). Association of common HFE gene mutations with coeliac disease results in protection against iron deficiency anaemia. GUT, 50, A19 - A19.
    • Patch C, Roderick P, Rosenberg W (2002). Feasibility and acceptability of two screening strategies for haemochromatosis, report of phase one of a randomised controlled trial..
    • Rosenberg WMC (2002). Success in treating mild chronic hepatitis C: different outcomes - new guidelines?. EUR J GASTROEN HEPAT, 14(6), 595 - 597.
    • Rosenberg WM, Christie J, Brooks C, Fleming K, Sadler HM (2002). The severity of hepatic inflammation predicts severity of heaptic fibrosis in chronic hepatitis C..
    • Khakoo SI, Brooks CL, Alexander G, Howell M, Rosenberg W (2002). Natural killer (NK) cell receptor genotypes in hepatitis C virus infection..
    • Semper AE, Libri N, Sanders E, Rosenberg WM (2002). IL-10 production by dendritic cells is enhanced by cross linking the HCV receptor CD81..
    • Lancaster T, Sanders E, Christie JML, Brooks C, Green S, Rosenberg WMC (2002). Quantitative and functional differences in CD8(+) lymphocyte responses in resolved acute and chronic hepatitis C virus infection. J VIRAL HEPATITIS, 9(1), 18 - 28.
    • Butterworth JR, Cooper BT, Rosenberg WMC, Purkiss M, Jobson S, Hathaway M, Briggs D, Howell WMC, Wood GM, Adams DH, Iqbal TH (2002). The role of hemochromatosis susceptibility gene mutations in protecting against iron deficiency in celiac disease.. Gastroenterology, 123(2), 444 - 449. doi:10.1053/gast.2002.34778
    • Brooks CL, Rosenberg WM (2002). Assessment and management of chronic hepatitis C infection.. Clin Med, 2(4), 302 - 306.
    • Stein K, Rosenberg W, Wong J (2002). Cost effectiveness of combination therapy for hepatitis C: a decision analytic model.. Gut, 50(2), 253 - 258.

    2001

    • Rosenberg WMC, MacDonald D (2001). CD44 regulation and function in Ulcerative Colitits. GUT, 48, A72 - A73.
    • Stevenson FK, Rosenberg W (2001). DNA vaccination: a potential weapon against infection and cancer.. Vox Sang, 80(1), 12 - 18.
    • Sanders EA, Fowkes LA, Holloway JA, Brooks CL, Rosenberg WM (2001). Impaired mixed leucocyte reaction and altered phenotype of dendritic cells in chronic hepatitis C.. HEPATOLOGY, 34(4), 434A - 434A.
    • Sanders EA, Xhu D, Spellerberg M, King K, Stevenson F, Rosenberg WM (2001). A DNA vaccine for HCV.. HEPATOLOGY, 34(4), 559A - 559A.
    • Brooks CL, Sanders EA, Wright MC, Trim J, Rosenberg WM (2001). Activated human hepatic stellate cells express ICAM-1 which can be conditionally up-regulated by TNF-alpha and IFN-gamma.. HEPATOLOGY, 34(4), 520A - 520A.
    • Earl S, Littleford S, Sanders EA, Howell M, Alexander GJ, Rosenberg WM (2001). Genetic susceptibility to liver fibrosis in Hepatitis C.. HEPATOLOGY, 34(4), 438A - 438A.
    • Purkiss M, Field-Smith A, Howell M, Rosenberg WM (2001). HFE mutations protect against iron deficiency.. HEPATOLOGY, 34(4), 505A - 505A.
    • Rosenberg WM, Burt A, Hubscher S, Roskams T, Voelker M, Becka M, Arthur MJ (2001). Serum markers predict liver fibrosis.. HEPATOLOGY, 34(4), 396A - 396A.
    • Patch C, Rosenberg W, Roderick P (2001). Comparison of two screening strategies for haemochromatosis: A pilot study investigating uptake, feasibility and cost. JOURNAL OF MEDICAL GENETICS, 38, S31 - S31.
    • Mc Rosenberg W, MacDonald DC (2001). CD44 regulation and function in Ulcerative Colitits. GASTROENTEROLOGY, 120(5), A519 - A519.

    2000

    • Mc Rosenberg W, Burt A, Becka M, Voelker M, Arthur MJ (2000). Automated assays of serum markers of liver fibrosis predict histological hepatic fibrosis.. HEPATOLOGY, 32(4), 183A - 183A.
    • Jackson CL, Sanders EA, Rosenberg WM (2000). CD4+t lymphocyte proliferation assays do not differentiate between patients with varying severity of liver disease in chronic hepatitis C infection.. HEPATOLOGY, 32(4), 264A - 264A.
    • Littleford S, Howell M, Mc Rosenberg W (2000). The association of cytokine polymorphisms with severe liver fibrosis in chronic hepatitis C infection.. HEPATOLOGY, 32(4), 274A - 274A.
    • Patch C, Rosenberg W (2000). Genetic testing for haemochromatosis: A survey of UK genetic centres. JOURNAL OF HEPATOLOGY, 32, 227 - 227. doi:10.1016/S0168-8278(00)81197-6
    • Elwyn G, Rosenberg W, Edwards A, Chatham W, Jones K, Matthews S, Macbeth F (2000). Diaries of evidence-based tutors: beyond 'numbers needed to teach'.... J Eval Clin Pract, 6(2), 149 - 154.
    • Robson KJH, Merryweather-Clark AT, Pointon JJ, Shearman JD, Halsall DJ, Kelly A, Cox TM, Rosenberg WM, Howell M, Eccles D, Patch C, Fowler AV, Wallace DF, Camaschella C, Roetto A, Zecchina G, De Gobbi M, Gasparini P, Cadet E, Vandwalle JL, Capron D, Rochette J, Borot N, Demangel C, Dery R, Vinel JP, Pascal JP, Coppin H, Roth MP (2000). Diagnosis and management of haemochromatosis since the discovery of the HFE gene: A European experience. British Journal of Haematology, 108(1), 31 - 39.
    • Rosenberg W (2000). Screening and shouting about HCV.. Gut, 47(2), 165 - 166.

    1999

    • Thompson FM, Jackson CL, Rosenberg WM (1999). CD4+T lymphocyte proliferative responses to hepatitis C non-structural NS3 region differentiate patients with mild and severe hepatitis.. HEPATOLOGY, 30(4), 459A - 459A.
    • Christie JML, Chapel H, Chapman RW, Rosenberg WMC (1999). Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. HEPATOLOGY, 30(4), 1037 - 1044.
    • Jackson CL, Thompson FM, Turner S, Howell WM, Rosenberg WM (1999). The MHC class II molecule DQB1*0301 is associated with HCV infection but mild chronic hepatitis C.. HEPATOLOGY, 30(4), 208A - 208A.
    • Leal P, Stein K, Rosenberg W (1999). What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?. J Med Screen, 6(3), 124 - 131.
    • Rosenberg W, Howell M, Roderick P, Eccles D, Day I (1999). Hereditary haemochromatosis should be more widely known about.. BMJ, 318(7196), 1486 - 1487.
    • Rosenberg W (1999). Mechanisms of immune escape in viral hepatitis.. Gut, 44(5), 759 - 764.
    • Barnes J, Stein A, Rosenberg W (1999). Evidence based medicine and evaluation of mental health services: methodological issues and future directions. ARCH DIS CHILD, 80(3), 280 - 285.
    • Rosenberg W (1999). Sex and drugs and HCV?. Gut, 45(1), 7 - 8.

    1998

    • Rosenberg WMC, Deeks J, Lusher A, Snowball R, Dooley G, Sackett D (1998). Improving searching skills and evidence retrieval. J ROY COLL PHYS LOND, 32(6), 557 - 563.
    • Worwood M, Bowen DJ, Burnett AK, Jackson HA, Lawless S, Raha-Chowdhury R, Shearman JD, Wallace DF, Dooley JS, Partridge J, Walker AP, Bomford A, Rosenberg WMC, Merryweather-Clarke AT, Robson KJH, Pointon JJ (1998). H63D is an haemochromatosis associated allele - Reply. GUT, 43(3), 441 - 442.
    • Christie J, Healey C, Fleming K, Chapman R, Rosenberg W (1998). Genetic variation in Immune epitopes in core and envelope regions of hepatitis C virus. GUT, 43(1), 159 - 159.
    • Pointon JJ, Stone C, Shearman JD, Merryweather-Clarke AT, Rosenberg WM, Robson KJ (1998). More microsatellite markers around D6S105.. Mol Cell Probes, 12(3), 181 - 184. doi:10.1006/mcpr.1998.0162
    • Christie JML, Fleming K, Chapman RW, Rosenberg WMC (1998). CD8(+) T lymphocyte (CD8(+)L) responses in acute and chronic hepatitis C virus (HCV) infection.. GASTROENTEROLOGY, 114(4), A1227 - A1227.
    • Shanahan J, Rosenberg W, Chapman RW, Fleming KA (1998). Deposition of complement C9 in primary sclerosing cholangitis (PSC).. GASTROENTEROLOGY, 114(4), A1340 - A1340.
    • Christie J, Fleming K, Chapman R, Rosenberg W (1998). CD8+ lymphocyte (CD8+L) responses in acute hepatitis C virus (HCV) infection. GUT, 42, A21 - A21.
    • Shearman JD, Pointon JJ, Merryweather-Clarke AT, Stone C, Horsley SW, Kearney L, Rosenberg WM, Robson KJ (1998). Rapid mapping of markers applying vectorette technology to YAC fragmentation allows easy assembly of a high-density STS bacterial clone contig spanning the markers D6S1260-D6S1918.. Mamm Genome, 9(3), 220 - 225.
    • Shanahan J, Rosenberg W, Chapman R, Fleming K (1998). Deposition of complement C 9 in primary sclerosing cholangitis.. JOURNAL OF PATHOLOGY, 186, 32A - 32A.
    • Fairbanks VF, Brandhagen DJ, Thibodeau SN, Snow K, Wollan PC, Worwood M, Bowen DJ, Burnett AK, Jackson HA, Lawless S, Raha-Chowdhury R, Shearman JD, Wallace DF, Dooley JS, Partridge J, Walker AP, Bomford A, Rosenberg WMC, Merryweather-Clarke AT, Robson KJH, Pointon JJ, Powell LW, Goldwurm S (1998). H63D is an haemochromatosis associated allele (multiple letters). Gut, 43(3), 441 - 442.

    1997

    • Robson KJ, Shearman JD, Merryweather-Clarke AT, Pointon JJ, Rosenberg WM, Walker AP, Dooley JS, Bomford A, Raha-Chowdhury R, Worwood M (1997). Haemochromatosis: a gene at last?. Journal of Medical Genetics, 34, 148 - 151.
    • Worwood M, Shearman JD, Wallace DF, Dooley JS, Merryweather-Clarke AT, Pointon JJ, Rosenberg WMC, Bowen DJ, Burnett AK, Jackson HA, Lawless S, Raha-Chowdhury R, Partridge J, Williams R, Bomford A, Walker AP, Robson KJHTUKHC (1997). A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut, 41, 841 - 844.
    • Christie J, Healey C, Fleming K, Chapel H, Chapman R, Rosenberg W (1997). Conservation within cytotoxic T lymphocyte epitopes in hepatitis C virus in chronic infection.. GASTROENTEROLOGY, 112(4), A1243 - A1243.
    • Christie JML, Dike AE, Mitchell SA, Kurtz JB, Teo C, Rosenberg W, Fleming K, Chapman RW (1997). Incidence and outcome of hepatitis C infection in blood product recipients: Experience of the Oxford blood centre within the National HCV Lookback Program.. HEPATOLOGY, 26(4), 66 - 66.
    • Christie JML, Healey CJ, Watson J, Wong VS, Duddridge M, Snowden N, Rosenberg WMC, Fleming KA, Chapel H, Chapman RWG (1997). Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. CLIN EXP IMMUNOL, 110(1), 4 - 8.

    1996

    • Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (1996). Evidence based medicine: what it is and what it isn't.. BMJ, 312(7023), 71 - 72.
    • Healey C, McAdam S, Plebanski M, Chapman R, Rosenberg W (1996). Cytotoxic T lymphocyte epitopes in hepatitis C virus identified with HLA assembly assays.. GASTROENTEROLOGY, 110(4), A1209 - A1209.
    • Murray N, Jackson D, Rosenberg W (1996). CD44 V3 and V6 expression on colonic epithelial cells is induced by interleukin 4.. GASTROENTEROLOGY, 110(4), A975 - A975.
    • Rosenberg WMC, Sackett DL (1996). Justification de la medecine factuelle. Therapie, 51(3), 212 - 217.
    • Maynard A, Sackett DL, Rosenberg WMC, Muir Gray JA, Haynes RB, Richardson WS (1996). Cost effectiveness and equity are ignored [13]. British Medical Journal, 313(7050), 170 - 171.
    • Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS (1996). Evidence based medicine: What it is and what it isn't - It's about integrating individual clinical expertise and the best external evidence. BRIT MED J, 312(7023), 71 - 72.
    • Dong T, Boyd D, Rosenberg W, Alp N, Takiguchi M, McMichael A, Rowland-Jones S (1996). An HLA-B35-restricted epitope modified at an anchor residue results in an antagonist peptide.. Eur J Immunol, 26(2), 335 - 339. doi:10.1002/eji.1830260210
    • Healey C, Chrisite J, Lai M, Cerundolo V, Rosenberg W (1996). Mutations in a putative hepatitis B virus HLA-A1 cytotoxic T lymphocyte epitope. Affect binding and correlate with disease severity.. GASTROENTEROLOGY, 110(4), A1209 - A1209.
    • Shearman J, Pointon JJ, MerryweatherClarke A, Stone C, Rosenberg W, Robson K, Weatherall DJ, Bomford A, Williams R, Walker A, Dooley J, RahaChowdhury R, Worwood M (1996). Localization of the haemochromatosis gene locus.. GASTROENTEROLOGY, 110(4), A1320 - A1320.
    • Rosenberg WMC, Sackett DL (1996). Untitled. HEALTH ECON, 5(3), 272 - 272.
    • Rosenberg WMC, Sackett DL (1996). On the need for evidence-based medicine. THERAPIE, 51(3), 212 - 217.
    • Rosenberg WMC, Sackett DL (1996). A superabundance of evidence? Reply. J ROY SOC MED, 89(5), 299 - 299.
    • Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS (1996). Evidence based medicine - Reply. BRIT MED J, 313(7050), 170 - 171.
    • Christie J, Healey C, Watson J, Wong S, Durridge M, Snowdon N, Rosenberg W, Fleming K, Chapel H, Chapman R (1996). Treatment and outcome of acute hepatitis C infection in hypogammaglobulinaemia - 2 year follow-up of the UK Gammagard outbreak.. HEPATOLOGY, 24(4), 1089 - 1089.

    1995

    • Ilyas M, Abbasi AM, Talbot IC, Forbes A, Rosenberg W (1995). CD44v6 and CD44v3 expression in ulcerative colitis and Crohn's disease [16]. Lancet, 346(8969), 256 - 256.
    • Sackett DL, Rosenberg WMC (1995). The need for evidence-based medicine. J ROY SOC MED, 88(11), 620 - 624.
    • Mant J, Hicks N, Rosenberg W, Sackett D (1995). How to use overviews of prevention trials to treat individual patients. Cerebrovascular Diseases, 6(SUPPL. 1), 34 - 40.
    • SACKETT DL, ROSENBERG WMC (1995). ON THE NEED FOR EVIDENCE-BASED MEDICINE. HEALTH ECON, 4(4), 249 - 254.
    • Fitzmaurice DA, Charlton BG, Griffiths M, Dearlove O, Sharples A, OBrien K, Dunkley C, Jones GW, Sagar SM, Smith BH, Miles A, Mitchell ABS, Rosenberg W, Donald A (1995). Evidence based medicine [2]. British Medical Journal, 311(6999), 257 - 259.
    • SACKETT DL, ROSENBERG WMC (1995). ON THE NEED FOR EVIDENCE-BASED MEDICINE. J PUBLIC HEALTH MED, 17(3), 330 - 334.
    • ROSENBERG WMC, PRINCE C, KAKLAMANIS L, JACKSON D, SIMMONS DLI, JEWELL DP, CHAPMAN RW, TROWELL JM, BELL JI (1995). ULCERATIVE-COLITIS IS DIFFERENTIATED FROM OTHER COLONIC INFLAMMATION BY CD44-V3 AND CD44-V6 EXPRESSION. GASTROENTEROLOGY, 108(4), A906 - A906.
    • Rosenberg W, Donald A (1995). Evidence based medicine: an approach to clinical problem-solving.. BMJ, 310(6987), 1122 - 1126.
    • ROSENBERG W, DONALD A (1995). EVIDENCE BASED MEDICINE - REPLY. BRITISH MEDICAL JOURNAL, 311(6999), 259 - 259.
    • ROSENBERG WMC, PRINCE C, KAKLAMANIS L, FOX SB, JACKSON DG, SIMMONS DL, CHAPMAN RW, TROWELL JM, JEWELL DP, BELL JI (1995). INCREASED EXPRESSION OF CD44V6 AND CD44V3 IN ULCERATIVE-COLITIS BUT NOT COLONIC CROHNS-DISEASE. LANCET, 345(8959), 1205 - 1209.

    1994

    • SATSANGI J, JEWELL DP, ROSENBERG WMC, BELL JI (1994). GENETICS OF INFLAMMATORY BOWEL-DISEASE. GUT, 35(5), 696 - 700.
    • MEHAL WZ, GREGORY WL, LO YMD, CROSS SJ, FLEMING KA, BASSENDINE MF, JAMES OFW, CAMPBELL RD, CHAPMAN RW, ROSENBERG WMC (1994). DEFINING THE IMMUNOGENETIC SUSCEPTIBILITY TO PRIMARY BILIARY-CIRRHOSIS. HEPATOLOGY, 20(5), 1213 - 1219.
    • YOUNG RP, DEKKER JW, WORDSWORTH BP, SCHOU C, PILE KD, MATTHIESEN F, ROSENBERG WMC, BELL JI, HOPKIN JM, COOKSON WOCM (1994). HLA-DR AND HLA-DP GENOTYPES AND IMMUNOGLOBULIN-E RESPONSES TO COMMON MAJOR ALLERGENS. CLIN EXP ALLERGY, 24(5), 431 - 439.
    • SATSANGI J, ROSENBERG WMC, JEWELL DP (1994). THE PREVALENCE OF INFLAMMATORY BOWEL-DISEASE IN RELATIVES OF PATIENTS WITH CROHNS-DISEASE. EUR J GASTROEN HEPAT, 6(5), 413 - 416.
    • Klenerman P, Rowland-Jones S, McAdam S, Edwards J, Daenke S, Lalloo D, Köppe B, Rosenberg W, Boyd D, Edwards A (1994). Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants.. Nature, 369(6479), 403 - 407. doi:10.1038/369403a0

    1993

    • Sutton J, Rowland-Jones S, Rosenberg W, Nixon D, Gotch F, Gao XM, Murray N, Spoonas A, Driscoll P, Smith M (1993). A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides.. Eur J Immunol, 23(2), 447 - 453. doi:10.1002/eji.1830230222
    • MEHAL WZ, GREGORY W, CROSS SJ, FLEMING KA, CAMPBELL RD, JAMES OFW, BASSENDINE MF, CHAPMAN RW, ROSENBERG WMC (1993). LOCALIZATION OF THE IMMUNOGENETIC SUSCEPTIBILITY IN PRIMARY BILIARY-CIRRHOSIS (PBC). GASTROENTEROLOGY, 104(4), A953 - A953.
    • MOSS PAH, ROSENBERG WMC, ZINTZARAS E, BELL JI (1993). CHARACTERIZATION OF THE HUMAN T-CELL RECEPTOR ALPHA-CHAIN REPERTOIRE AND DEMONSTRATION OF A GENETIC INFLUENCE ON V-ALPHA USAGE. EUR J IMMUNOL, 23(5), 1153 - 1159.
    • Fowlie S, Jones HW, Hignett C, Rosenberg W, Chapman RW (1993). Investigation of colonic symptoms: the value of flexible sigmoidoscopy.. Br J Clin Pract, 47(4), 185 - 186.
    • Rowland-Jones SL, Powis SH, Sutton J, Mockridge I, Gotch FM, Murray N, Hill AB, Rosenberg WM, Trowsdale J, McMichael AJ (1993). An antigen processing polymorphism revealed by HLA-B8-restricted cytotoxic T lymphocytes which does not correlate with TAP gene polymorphism.. Eur J Immunol, 23(8), 1999 - 2004. doi:10.1002/eji.1830230841
    • MEHAL WZ, GREGORY W, CROSS SJ, FLEMING KA, CAMPBELL RD, JAMES OFW, BASSENDINE MF, CHAPMAN RW, ROSENBERG WMC (1993). COMPLEMENT C4B2 AND HLA DR8 GENOTYPING EXPLAINS THEIR KNOWN ASSOCIATIONS IN PBC. HEPATOLOGY, 18(4), A216 - A216.
    • ROSENBERG WMC, RYLEY NG, TROWELL JM, MCGEE JO, CHAPMAN RW (1993). DEXTROPROPOXYPHENE INDUCED HEPATOTOXICITY - A REPORT OF 9 CASES. J HEPATOL, 19(3), 470 - 474.
    • Powis SH, Rosenberg WM, Hall M, Mockridge I, Tonks S, Ivinson A, Ciclitira PJ, Jewell DP, Lanchbury JS, Bell JI (1993). TAP1 and TAP2 polymorphism in coeliac disease.. Immunogenetics, 38(5), 345 - 350.

    1992

    • CROTTY B, ROSENBERG WMC, ARONSON JK, JEWELL DP (1992). INHIBITION OF BINDING OF INTERFERON-GAMMA TO ITS RECEPTOR BY SALICYLATES USED IN INFLAMMATORY BOWEL-DISEASE. GUT, 33(10), 1353 - 1357.
    • MOSS PAH, ROSENBERG WMC, BELL JI (1992). THE HUMAN T-CELL RECEPTOR IN HEALTH AND DISEASE. ANNU REV IMMUNOL, 10, 71 - 96.
    • ROSENBERG WMC, BUSHELL A, HIGGINS RM, WORDSWORTH BP, WOOD KJ, BELL JI, MORRIS PJ (1992). ISOLATED HLA-DP MISMATCHES BETWEEN DONORS AND RECIPIENTS DO NOT INFLUENCE THE FUNCTION OR OUTCOME OF RENAL-TRANSPLANTS. HUM IMMUNOL, 33(1), 5 - 9.
    • ROSENBERG WMC, MOSS PAH, BELL JI (1992). MOLECULAR ASPECTS OF AUTOIMMUNITY - A REVIEW.
    • ROSENBERG WMC, MOSS PAH, BELL JI (1992). VARIATION IN HUMAN T-CELL RECEPTOR V-BETA AND J-BETA REPERTOIRE - ANALYSIS USING ANCHOR POLYMERASE CHAIN-REACTION. EUR J IMMUNOL, 22(2), 541 - 549.

    1991

    • WORDSWORTH BP, STEDEFORD J, ROSENBERG WMC, BELL JI (1991). LIMITED HETEROGENEITY OF THE HLA CLASS-II CONTRIBUTION TO SUSCEPTIBILITY TO RHEUMATOID-ARTHRITIS IS SUGGESTED BY POSITIVE ASSOCIATIONS WITH HLA-DR4, DR1 AND DRW10. BRIT J RHEUMATOL, 30(3), 178 - 180.
    • LOVERIDGE JA, ROSENBERG WMC, KIRKWOOD TBL, BELL JI (1991). THE GENETIC CONTRIBUTION TO HUMAN T-CELL RECEPTOR REPERTOIRE. IMMUNOLOGY, 74(2), 246 - 250.
    • MOSS PAH, MOOTS RJ, ROSENBERG WMC, ROWLANDJONES SJ, BODMER HC, MCMICHAEL AJ, BELL JI (1991). EXTENSIVE CONSERVATION OF ALPHA-CHAIN AND BETA-CHAIN OF THE HUMAN T-CELL ANTIGEN RECEPTOR RECOGNIZING HLA-A2 AND INFLUENZA-A MATRIX PEPTIDE. P NATL ACAD SCI USA, 88(20), 8987 - 8990.

    1990

    • Rosenberg W, Ireland A, Jewell DP (1990). High-dose methylprednisolone in the treatment of active ulcerative colitis.. J Clin Gastroenterol, 12(1), 40 - 41.
    • MANTZARIS GJ, ROSENBERG WMC, JEWELL DP (1990). THE IMMUNOLOGY OF CELIAC-DISEASE. SPRINGER SEMIN IMMUN, 12(2-3), 219 - 229.

    1989

    • ROSENBERG WMC, WORDSWORTH BP, JEWELL DP, BELL JI (1989). A LOCUS TELOMERIC TO HLA-DPB ENCODES SUSCEPTIBILITY TO CELIAC-DISEASE. IMMUNOGENETICS, 30(4), 307 - 310.
    • ROSENBERG W, WORDSWORTH P, BELL J, JEWELL D (1989). DP ALLELES DO NOT INDEPENDENTLY CONFER SUSCEPTIBILITY TO CELIAC-DISEASE. GUT, 30(10), A1512 - A1512.

    1988

    • IRELAND A, ROSENBERG W, JEWELL D (1988). HIGH-DOSE METHYLPREDNISOLONE IN THE TREATMENT OF ACTIVE ULCERATIVE-COLITIS. GUT, 29(10), A1466 - A1466.

    1986

    • Rosenberg W, Parkes J, Jenkins A, Denham MJ, Royston JP, Sullens CM, O'Neill C, Dobbs SM (1986). Making a rehabilitation hospital for the elderly work.. Health Trends, 18(3), 66 - 71.

    1984

    • ARCHER CB, SCOTT GW, ROSENBERG WMC, MACDONALD DM (1984). PROGRESSIVE BACTERIAL SYNERGISTIC GANGRENE IN PATIENT WITH DIABETES-MELLITUS. J ROY SOC MED, 77, 1 - 3.

    • Guha IN, Parkes J, Roderick P, Chattopadhay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM (). Non-invasive markers of fibrosis in non-alcoholic fatty liver disease: validating the European Liver Fibrosis panel and exploring simple markers.. Hepatology, , - .